Intracameral medication use requires careful consideration of pros and cons

Article

When thinking about administering medications intracamerally during cataract surgery, it is important to consider whether their potential benefits are worth the risk.

When thinking about administering medications intracamerally during cataract surgery, it is important to consider whether their potential benefits are worth the risk, said Nick Mamalis, MD, at Spotlight on Cataracts 2007.

Intracameral medications may be used in cataract surgery for anesthesia, pupil dilation, and to prevent inflammation and endophthalmitis. Their advantages include ease of delivery, elimination of toxicity of topical drops, avoidance of compliance issues, and possibly enhanced efficacy.

However, there are a number of downsides. Toxicity is an important risk that can occur through multiple mechanisms, which can be related to improper concentration, pH, or osmolarity. In addition, all medications used intracamerally should be preservative-free, but it is also important to be aware of toxicity related to stabilizing agents, such as are found in preservative-free epinephrine. Infectious contamination is another safety concern as is the potential for incompatibility when multiple drugs are combined.

"There are many trade-offs to consider when weighing the pros and cons of using topical drops versus intracameral medications. Intracameral medication safety can be improved if we could eliminate 'kitchen pharmacy,'" Dr. Mamalis said.

"We need sterile, pre-mixed, preservative-free, unit-dose products, and the ophthalmology community needs to work with the FDA and industry to achieve that goal," he added.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.